{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:40:17Z","timestamp":1786639217620,"version":"build-2736575974"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seven electronic databases were searched, including PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, and Chinese Biomedical Literature Service System. Relevant literature from inception to the end of December 2025 was retrieved. Studies meeting the criteria were selected, and network meta-analysis was performed using Stata 16 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 54 studies involving 7,290 patients were included. Network meta-analysis indicated that olopatadine, mizolastine, bilastine, and levocetirizine were more effective than placebo in improving total symptom scores. All 10 drugs were superior to placebo in reducing itching scores, although only fexofenadine achieved statistical significance. For reducing wheal scores, ebastine was significantly more effective than mizolastine and loratadine. Regarding adverse reactions, no significant differences were observed between any of the drugs and placebo, with fexofenadine having the lowest adverse reaction rate. Sensitivity analyses excluding highrisk studies confirmed the robustness of findings across all outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on current evidence, olopatadine at licensed dose exhibited the best efficacy in reducing total symptom scores. Fexofenadine was most effective for improving itching scores and ebastine was optimal for reducing wheal scores. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1880701","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:09:21Z","timestamp":1786637361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zixuan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University, Hebei Province Key Laboratory of Environment and Human Health","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxu","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuotao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin Institute of Integrative Dermatology","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international eaaci\/ga2len\/euroguiderm\/apaaaci guideline for the definition, classification, diagnosis, and management of urticaria.","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1056\/NEJMc2212742","article-title":"Chronic urticaria.","volume":"387","author":"Descamps","year":"2022","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis.","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy."},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13223-019-0375-9","article-title":"CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.","volume":"15","author":"Fein","year":"2019","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/0253-7613.62399","article-title":"Loratadine versus levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety.","volume":"42","author":"Anuradha","year":"2010","journal-title":"Indian J Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00128071-200708010-00005","article-title":"Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.","volume":"8","author":"Ortonne","year":"2007","journal-title":"Am J Clin Dermatol."},{"key":"B7","first-page":"387","article-title":"Efficacy of levocetirizine hydrochloride in the treatment of chronic urticaria: a clinical observation.","author":"Zhang","year":"2010","journal-title":"J Pharmaceut Central South China."},{"key":"B8","first-page":"185","article-title":"Evaluation of the efficacy of levocetirizine in chronic idiopathic urticaria.","author":"Zhou","year":"2017","journal-title":"J Contemp Med Discourse."},{"key":"B9","first-page":"1362","article-title":"Efficacy of levocetirizine hydrochloride in the treatment of chronic idiopathic urticaria.","author":"Fang","year":"2009","journal-title":"J Integ Med Res Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.19335\/j.cnki.2096-1219.2023.03.024","article-title":"Analysis of the efficacy of rupatadine fumarate in the treatment of chronic idiopathic urticaria and its impact on \u2018patients\u2019 psychological state.","volume":"9","author":"Yunchang","year":"2023","journal-title":"J Smart Healthcare."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU.","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy."},{"key":"B12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4168\/aair.2020.12.4.563","article-title":"The KAAACI\/KDA evidence-based practice guidelines for chronic spontaneous urticaria in Korean adults and children: part 1. definition, methodology and first-line management.","volume":"12","author":"Song","year":"2020","journal-title":"Allergy Asthma Immunol Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/bjd.20415","article-title":"Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the centre of evidence of the french society of dermatology.","volume":"185","author":"Hacard","year":"2021","journal-title":"Br J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamadermatol.2021.3237","article-title":"Evaluation of pharmacologic treatments for H1 antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis.","volume":"157","author":"Nochaiwong","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jaip.2023.03.058","article-title":"Comparative safety profiles of individual second-generation H1-antihistamines for the treatment of chronic urticaria: a systematic review and network meta-analysis of randomized controlled trials.","volume":"11","author":"Chaichan","year":"2023","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B16","first-page":"752","article-title":"Efficacy and safety of desloratadine in the treatment of urticaria: a meta-analysis.","volume":"34","author":"Gang","year":"2019","journal-title":"J Clinical Focus."},{"key":"B17","first-page":"40","article-title":"Efficacy and safety of eight antihistamines in the treatment of chronic urticaria: a network meta-analysis.","volume":"32","author":"Siwen","year":"2020","journal-title":"J Tianjin Pharmacy."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/s0091-6749(99)70091-6","article-title":"A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.","volume":"104","author":"Finn","year":"1999","journal-title":"J Allergy Clin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/ijd.12250","article-title":"Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial.","volume":"53","author":"Dakhale","year":"2014","journal-title":"Int J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0019-5154.159621","article-title":"Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: a randomized, double-blind, comparative, parallel group trial.","volume":"61","author":"Dakhale","year":"2016","journal-title":"Indian J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1398-9995.2009.02217.x","article-title":"Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.","volume":"65","author":"Zuberbier","year":"2010","journal-title":"Allergy."},{"key":"B22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1398-9995.2008.01893.x","article-title":"Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.","volume":"64","author":"Potter","year":"2009","journal-title":"Allergy."},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.alit.2018.06.002","article-title":"Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: a double-blind, randomized, multicenter, placebo-controlled clinical trial.","volume":"68","author":"Hide","year":"2019","journal-title":"Allergol Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1398-9995.1996.tb04616.x","article-title":"Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria.","volume":"51","author":"Brostoff","year":"1996","journal-title":"Allergy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1081-1206(10)62515-X","article-title":"Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.","volume":"84","author":"Nelson","year":"2000","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.alit.2016.08.004","article-title":"Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II\/III study.","volume":"66","author":"Hide","year":"2017","journal-title":"Allergol Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/ijd.12733","article-title":"Levocetirizine and rupatadine in chronic idiopathic urticaria.","volume":"54","author":"Johnson","year":"2015","journal-title":"Int J Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/09546634.2012.750414","article-title":"Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety.","volume":"24","author":"Sil","year":"2013","journal-title":"J Dermatolog Treat."},{"key":"B29","first-page":"1444","article-title":"Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety.","volume":"10","author":"Maiti","year":"2011","journal-title":"J Drugs Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1398-9995.2007.01330.x","article-title":"Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study.","volume":"62","author":"Gimenez-Arnau","year":"2007","journal-title":"Allergy."},{"key":"B31","first-page":"246","article-title":"Clinical comparative observation of desloratadine and cetirizine hydrochloride in the treatment of chronic urticaria.","year":"2006","journal-title":"J Pract Diagn Treatment."},{"key":"B32","first-page":"240","article-title":"Comparison of the efficacy and safety of desloratadine and mizolastine in the treatment of chronic urticaria.","author":"Chen","year":"2004","journal-title":"J Dermatol Venereol Lingnan."},{"key":"B33","first-page":"39","article-title":"Study on the clinical value of desloratadine in patients with chronic urticaria.","author":"Ma","year":"2016","journal-title":"Guide Chin Med."},{"key":"B34","first-page":"911","article-title":"Efficacy and serum factor modulation of levocetirizine in chronic urticaria.","author":"Tang","year":"2013","journal-title":"J Ningxia Med Univ."},{"key":"B35","first-page":"143","article-title":"Clinical efficacy of desloratadine in the treatment of chronic urticaria.","author":"Liang","year":"2012","journal-title":"J Contemp Med."},{"key":"B36","first-page":"101","article-title":"Clinical efficacy analysis of cetirizine in treating chronic urticaria.","author":"Li","year":"2014","journal-title":"J Aesthetic Med China."},{"key":"B37","first-page":"11","article-title":"A clinical study of cetirizine in the treatment of chronic urticaria.","author":"Li","year":"2006","journal-title":"J Dermatol Venereol."},{"key":"B38","first-page":"162","article-title":"Clinical study of fexofenadine in the treatment of chronic idiopathic urticaria.","author":"Mingchun","year":"2004","journal-title":"J China Trop Med."},{"key":"B39","first-page":"1271","article-title":"Efficacy and safety of rupatadine fumarate tablets in the treatment of chronic idiopathic urticaria.","author":"Xing","year":"2017","journal-title":"J Chin J Hosp Pharm."},{"key":"B40","first-page":"56","article-title":"Clinical study of the efficacy and safety of rupatadine fumarate tablets in the treatment of chronic urticaria.","author":"Sun","year":"2017","journal-title":"J Comprehens Oral Med."},{"key":"B41","first-page":"70","article-title":"A comparative clinical study of mizolastine and levocetirizine in the treatment of chronic idiopathic urticaria.","author":"Cai","year":"2005","journal-title":"J Food Pharmaceut."},{"key":"B42","first-page":"56","article-title":"A clinical observation of 50 cases of chronic idiopathic urticaria treated with mizolastine.","author":"Xu","year":"2002","journal-title":"J Chin J Integ Trad Western Med Dermatol Venereol."},{"key":"B43","first-page":"61","article-title":"A multicenter, randomized, parallel-group, controlled clinical trial of mizolastine in chronic idiopathic urticaria.","author":"Zhang","year":"2001","journal-title":"J Chin J Microbiol Immunol."},{"key":"B44","first-page":"482","article-title":"A randomized, double-blind study of mizolastine in chronic idiopathic urticaria.","author":"Guo","year":"2003","journal-title":"J West China School Med."},{"key":"B45","first-page":"181","article-title":"Clinical study of mizolastine in the treatment of chronic idiopathic urticaria.","author":"Wu","year":"2001","journal-title":"J Clin Dermatol."},{"key":"B46","first-page":"9","article-title":"A randomized, double-blind study of mizolastine in chronic urticaria.","author":"Liu","year":"2003","journal-title":"J Chin J Dermatol."},{"key":"B47","first-page":"1629","article-title":"A multicenter, clinical trial evaluating the efficacy and safety of olopatadine hydrochloride tablets in the treatment of chronic idiopathic urticaria.","author":"Chen","year":"2017","journal-title":"J Chin J Hosp Pharm."},{"key":"B48","first-page":"305","article-title":"Efficacy and safety of olopatadine hydrochloride in the treatment of chronic urticaria: an observational study.","author":"Ma","year":"2019","journal-title":"J Clin Dermatol."},{"key":"B49","first-page":"142","article-title":"Clinical efficacy and safety of olopatadine hydrochloride in the treatment of chronic urticaria.","author":"Wei","year":"2017","journal-title":"J Straits Pharmaceut Sci."},{"key":"B50","first-page":"526","article-title":"Clinical efficacy and safety study of fexofenadine hydrochloride capsules in the treatment of chronic idiopathic urticaria.","author":"Yan","year":"2006","journal-title":"J Tianjin Med Univ."},{"key":"B51","first-page":"872","article-title":"Observation of the efficacy of levocetirizine hydrochloride oral solution in 60 cases of chronic urticaria.","author":"Zhao","year":"2015","journal-title":"J Pract Med Techn."},{"key":"B52","first-page":"420","article-title":"A study of cetirizine hydrochloride tablets in the treatment of chronic idiopathic urticaria.","author":"Cheng","year":"2006","journal-title":"J Guiyang Med Univ."},{"key":"B53","first-page":"477","article-title":"A clinical study of cetirizine hydrochloride in the treatment of chronic idiopathic urticaria.","author":"Yin","year":"2003","journal-title":"J Clin Dermatol."},{"key":"B54","first-page":"922","article-title":"A comparative clinical study of ebastine and mizolastine in the treatment of chronic idiopathic urticaria.","author":"Cai","year":"2006","journal-title":"J Guangdong Med."},{"key":"B55","first-page":"307","article-title":"Clinical trial of ebastine in the treatment of chronic idiopathic urticaria.","author":"Zhi","year":"2004","journal-title":"J Clin Dermatol."},{"key":"B56","first-page":"135","article-title":"Observation of the efficacy of ebastine in the treatment of patients with chronic idiopathic urticaria.","author":"Lin","year":"2019","journal-title":"J Contemp Med."},{"key":"B57","first-page":"25","article-title":"Clinical study of ebastine in the treatment of chronic idiopathic urticaria.","author":"Deng","year":"2007","journal-title":"J China Med Front."},{"key":"B58","first-page":"101","article-title":"A multicenter, randomized, double-blind, parallel-controlled clinical study of ebastine in the treatment of chronic urticaria and its effects on the QTc interval.","author":"Qi","year":"2005","journal-title":"J Chin J New Drugs."},{"key":"B59","first-page":"2250","article-title":"A clinical study comparing two antihistamines in the treatment of chronic spontaneous urticaria.","author":"Gang","year":"2007","journal-title":"J Modern Med Public Health."},{"key":"B60","first-page":"47","article-title":"A randomized controlled trial comparing ebastine and cetirizine in the treatment of chronic idiopathic urticaria.","author":"Chen","year":"2006","journal-title":"J Chin J Leprosy Dermatol."},{"key":"B61","first-page":"162","article-title":"Efficacy and adverse reactions of ebastine tablets in the treatment of chronic urticaria.","author":"Daheng","year":"2024","journal-title":"J Famous Doctors."},{"key":"B62","first-page":"125","article-title":"Efficacy evaluation of levocetirizine hydrochloride dispersible tablets in patients with chronic urticaria.","volume":"35","author":"Yanling","year":"2022","journal-title":"J Med Inform."},{"key":"B63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.15912\/j.cnki.gocm.2023.26.023","article-title":"Clinical evaluation of the efficacy of rupatadine fumarate tablets in the treatment of chronic idiopathic urticaria.","volume":"21","author":"Weidong","year":"2023","journal-title":"J China Med Guidelines."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/CM9.0000000000003071","article-title":"Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: a multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial.","volume":"137","author":"Chen","year":"2024","journal-title":"Chin Med J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/picr.picr_28_23","article-title":"Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: open-label, randomized, parallel-group study.","volume":"14","author":"Sinha","year":"2023","journal-title":"Perspect Clin Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1880701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:09:27Z","timestamp":1786637367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1880701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":65,"alternative-id":["10.3389\/fmed.2026.1880701"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1880701","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1880701"}}